$ABBV · AbbVie Inc.

This SEC Form 4 filing discloses transactions by Nicholas Donoghoe, AbbVie’s Executive Vice President and Chief Business/Strategy Officer. On August 14, 2026, he exercised employee stock options to acquire 32,710 shares of AbbVie common stock at an exercise price of $79.02 per share. The options had been granted under the AbbVie Amended and Restated 2013 Incentive Stock Program and had become exercisable in annual increments between 2020 and 2022.

On the same day, Donoghoe sold all 32,710 of those shares at a price of $250.00 per share. Following the exercise and sale, he directly held 74,430 shares of AbbVie common stock. The filing indicates that no derivative securities remained beneficially owned by the reporting person after the transaction.

This is a routine Form 4 statement of changes in beneficial ownership, filed to report transactions by a corporate officer under Section 16 of the Securities Exchange Act of 1934. It does not describe a corporate event or change in AbbVie’s business.